NCT06611592View on ClinicalTrials.gov

Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD)

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

August 20, 2028

Study Completion Date

August 20, 2028

Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG

Pramipexole 0.088mg/tid

Week 1 - Week 16 (end of treatment): Oral administration of 0.088 mg/tid dose of pramipexole (0.125 mg of salt).

DRUG

Pramipexole 0.18 mg/tid

"Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2 -Week 16 (end of treatment): oral administration of 0.18 mg/tid dose of pramipexole (0.25 mg salt)."

DRUG

Pramipexole 0.35 mg/tid

"Week 1: oral administration of 0,088 mg/tid dose of pramipexole (0.125 mg salt).~Week 2: oral administration of a 0.18 mg/tid dose of pramipexole (0.25 mg salt).~Week 3 - Week 16 (end of treatment): oral administration of a 0.35 mg/tid dose of pramipexole (0.50 mg salt)."

Trial Locations (1)

4710-243

RECRUITING

Clinical Academic Center - Braga (2CA-Braga), Braga

All Listed Sponsors
lead

Clinical Academic Center (2CA-Braga)

OTHER